For example, the histone deacetylase (HDAC) inhibitor, including three FDA-approved molecules for treatments of T-cell lymphomas, SAHA (vorinostat), belinostat, and romidepsin, represent an important class of HIV LRAs that have been tested in clinical trials (72). This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.